Related Experiment Videos
Radiation sensitisation by nitric oxide releasing agents
J B Mitchell1, J A Cook, M C Krishna
1Radiation Biology Branch, National Cancer Institute, Bethesda, MD 20892, USA.
The British Journal of Cancer. Supplement
|July 1, 1996
Summary
Certain nitric oxide (NO) donor agents, specifically S-nitrosothiols like GSNO and SNAP, effectively radiosensitise hypoxic cells. This NO-mediated radiosensitisation shows promise for clinical applications in cancer therapy.
Area of Science:
- Radiation Oncology
- Cellular Biology
- Pharmacology
Background:
- Nitric oxide (NO) is known to sensitise hypoxic cells to ionising radiation.
- Hypoxic cells are resistant to radiation therapy, posing a challenge in cancer treatment.
Purpose of the Study:
- To evaluate four different nitric oxide (NO) donor agents for their ability to release NO and radiosensitise hypoxic cells.
- To compare the efficacy of S-nitrosothiol NO donors with other agents.
Main Methods:
- Assessment of NO release from four different NO donor agents.
- Evaluation of hypoxic cell radiosensitisation by these agents.
- Comparison of radiosensitisation efficacy with molecular oxygen.
Main Results:
- S-nitrosoglutathione (GSNO) and S-nitroso-N-acetylpenicillamine (SNAP) released sustained nitric oxide (NO) concentrations.
- GSNO and SNAP significantly radiosensitised hypoxic cells, with efficacy comparable to molecular oxygen.
- 3-morpholinosydnonimine (SIN-1) and sodium nitroprusside (SNP) did not release detectable NO or enhance hypoxic radiation response.
Conclusions:
- S-nitrosothiol NO donors (GSNO, SNAP) are effective in radiosensitising hypoxic cells.
- NO-mediated hypoxic cell radiosensitisation presents a potential new strategy for clinical cancer treatment.
- Selective delivery of NO donor drugs to hypoxic tumour cells could enhance therapeutic outcomes.